Helix BioPharma Corp (HBP):企業の財務・戦略的SWOT分析

【英語タイトル】Helix BioPharma Corp (HBP) - Financial and Strategic SWOT Analysis Review

GlobalDataが出版した調査資料(DATA904C0579)・商品コード:DATA904C0579
・発行会社(調査会社):GlobalData
・発行日:2018年7月
・ページ数:47
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Helix BioPharma Corp (HBP) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Helix BioPharma Corp (Helix) is a biopharmaceutical company with a focus in the field of cancer therapy. It develops drug candidates for the prevention and treatment of cancer. It develops drugs based on its proprietary technologies. DOS47, the company’s proprietary broad anti-cancer therapeutic platform has yielded two new drug product candidates, V-DOS47 and L-DOS47. V-DOS47 uses the company’s proprietary DOS47 technology conjugated to VEGFR target wide range of cancers and L-DOS47 is designed to treat inoperable, locally advanced, recurrent or metastatic non-small cell lung cancer (NSCLC). It also continues to actively pursue additional novel antibody based technologies for cell-based therapies. Helix is headquartered in Aurora, Ontario, Canada.

Helix BioPharma Corp Key Recent Developments

Jun 12,2018: Helix BioPharma Reports Fiscal Third Quarter 2018 Financial Results
Mar 22,2018: Helix BioPharma Welcomes Drs. Daniel Von Hoff, Kazimierz Roszkowski-Sliz and Robert Gillies to Its Scientific and Strategic Advisory Board
Mar 20,2018: Helix BioPharma Announces Fiscal Second Quarter 2018 Results
Dec 13,2017: Helix BioPharma Announces Fiscal First Quarter 2018 Results
Dec 01,2017: Helix BioPharma Announces Management Change

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 – About the Company 6
Helix BioPharma Corp – Key Facts 6
Helix BioPharma Corp – Key Employees 7
Helix BioPharma Corp – Key Employee Biographies 8
Helix BioPharma Corp – Major Products and Services 9
Helix BioPharma Corp – History 10
Helix BioPharma Corp – Company Statement 12
Helix BioPharma Corp – Locations And Subsidiaries 13
Head Office 13
Other Locations & Subsidiaries 13
Section 2 – Company Analysis 14
Company Overview 14
Helix BioPharma Corp – Business Description 15
Helix BioPharma Corp – Corporate Strategy 16
Helix BioPharma Corp – SWOT Analysis 17
SWOT Analysis – Overview 17
Helix BioPharma Corp – Strengths 17
Helix BioPharma Corp – Weaknesses 18
Helix BioPharma Corp – Opportunities 19
Helix BioPharma Corp – Threats 20
Helix BioPharma Corp – Key Competitors 21
Section 3 – Company Financial Ratios 22
Financial Ratios – Capital Market Ratios 22
Financial Ratios – Annual Ratios 23
Performance Chart 24
Financial Performance 24
Financial Ratios – Interim Ratios 25
Financial Ratios – Ratio Charts 26
Section 4 – Company’s Lifesciences Financial Deals and Alliances 27
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 27
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 28
Helix BioPharma Corp, Recent Deals Summary 29
Section 5 – Company’s Recent Developments 30
Mar 22, 2018: Helix BioPharma Welcomes Drs. Daniel Von Hoff, Kazimierz Roszkowski-Sliz and Robert Gillies to Its Scientific and Strategic Advisory Board 30
Mar 20, 2018: Helix BioPharma Announces Fiscal Second Quarter 2018 Results 31
Dec 13, 2017: Helix BioPharma Announces Fiscal First Quarter 2018 Results 33
Dec 01, 2017: Helix BioPharma Announces Management Change 34
Oct 27, 2017: Helix BioPharma Announces Fiscal 2017 Year-End Results and Provides Research and Development Program Update 35
Jul 17, 2017: Helix BioPharma Director Resigns 37
Jul 17, 2017: Helix BioPharma Director Resigns 38
Jun 13, 2017: Helix BioPharma Announces Fiscal Third Quarter 2017 Results 39
Mar 17, 2017: Helix BioPharma Announces Fiscal Second Quarter 2017 Results 41
Mar 07, 2017: Helix BioPharma Announces Strategic Management Changes 42
Section 6 – Appendix 43
Methodology 43
Ratio Definitions 43
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
Helix BioPharma Corp, Key Facts 6
Helix BioPharma Corp, Key Employees 7
Helix BioPharma Corp, Key Employee Biographies 8
Helix BioPharma Corp, Major Products and Services 9
Helix BioPharma Corp, History 10
Helix BioPharma Corp, Subsidiaries 13
Helix BioPharma Corp, Key Competitors 21
Helix BioPharma Corp, Ratios based on current share price 22
Helix BioPharma Corp, Annual Ratios 23
Helix BioPharma Corp, Interim Ratios 25
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 27
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 28
Helix BioPharma Corp, Recent Deals Summary 29
Currency Codes 43
Capital Market Ratios 43
Equity Ratios 44
Profitability Ratios 44
Cost Ratios 45
Liquidity Ratios 45
Leverage Ratios 46
Efficiency Ratios 46

List of Figures
Helix BioPharma Corp, Performance Chart (2013 - 2017) 24
Helix BioPharma Corp, Ratio Charts 26
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 27
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 28

★調査レポート[Helix BioPharma Corp (HBP):企業の財務・戦略的SWOT分析] (コード:DATA904C0579)販売に関する免責事項を必ずご確認ください。
★調査レポート[Helix BioPharma Corp (HBP):企業の財務・戦略的SWOT分析]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆